STL Index for: Adapalene
Tazarotene Lotion 0.045% for the Treatment of Acne (FP)
Topical retinoids are recommended as first-line therapy for most patients with acne. Tazarotene 0.045% lotion is a novel formulation that utilizes polymeric emulsion technology to improve tolerability and epidermal penetration.
Tazarotene Lotion 0.045% for the Treatment of Acne
Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.
Advances in Understanding Atrophic Acne Scarring and the Role of Adapalene/Benzoyl Peroxide
There have been important advances in our understanding of acne scarring. Acne scars can resolve, and their evolution is determined by a balance between matrix repair and degradation. Timely, effective management of acne can minimize risk of subsequent acne scarring.
A Clinician’s Guide to Treating Acne
In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.
A Physician’s Guide to Treating Acne
Acne is among the most common dermatological conditions seen in primary care. In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.
Acne in the Post-Adolescent Patient
For the purposes of this article, the focus will be on the topical treatment of post-adolescent mild to moderate acne. A selection of over-the-counter and prescription based topical treatments are discussed below.
The New Canadian Guideline for Acne Treatment
Physicians will be particularly reassured if the suggested guidelines are supported by scientific evidence. This new Canadian clinical guideline for the treatment of acne was developed taking into account new data published up to March 2015, as well as expert opinion and clinical experience.
Skin Treatments Introduced in 2015
An overview and update of skin treatments introduced in 2015: Quick overview of drug name, indications and regulatory status. Deoxycholic acid injection, 5-fluorouracil 0.5% + salicylic acid 10% solution, Adapalene 0.3% + benzoyl peroxide 2.5% gel, and more are covered.
Update on Drugs and Drug News: September-October 2015
Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)
Advances in Acne Management and Patient Adherence
Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. Treatment options, such as light based therapy and systemic therapy, as well as CIS-Isotretinoin (Epuris™) that increases absorption are discussed as well as patient adherence.
Advances in Topical Acne Therapy: New Molecules, Vehicles and Delivery Mechanisms
Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. The most frequently used therapeutic agents for acne are topical. This article focuses on the role of vehicles and advancements in this area.
Adjunctive Skin Care for Acne (Pharmacist Edition)
Acne is among the most common dermatological disorders seen by dermatologists, affecting approximately 85% of people between the ages of 12 and 24 years. The use of adjunctive cleansers and moisturizers can help mitigate treatment side effects and subsequently enhance therapeutic efficacy.
Skin Treatments Introduced in 2012
Skin Treatments Introduced in 2012. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US), Ingenol mebutate gel (0.015%, 0.05%) Picato®and more are covered.
Skin Treatments Introduced in 2012
An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.
Antibiotic Resistance in Acne Treatment
Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.
Dapsone 5% Gel: A New Option in Topical Therapy for Acne
Dapsone 5% gel for the topical treatment for acne represents the first new anti-acne agent to gain North American regulatory approval in the past decade. Dapsone's utility is attributable to its anti-inflammatory and antimicrobial properties, with more prominent effects occurring in inflammatory lesions.
What’s New in Acne Treatment in Canada?
Acne vulgaris is the most common skin disorder affecting children and young adults in North America. This article discusses combination therapy, and simplifying treatment plans in order to increase patient adherence, which is often a critical problem in treating acne.
The Noncompliant Patient with Acne
Patient adherence remains a serious challenge with acne patients. This article will review this problem and offer a number of suggestions, including dosing considerations and the use of laser/light devices, to better treat the non-adherent patient.
Newer Approaches in Topical Combination Therapy for Acne
Acne vulgaris is a common chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses the multifactorial nature of acne pathophysiology, therapeutics, and mechanism of action.
Topical Approaches in Combination Therapy for Acne (FP Edition)
Acne vulgaris is a chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses pathophysiology, sebum production, keratinization, and the role of P.acnes in acne formation.
Topical Acne Therapy Advances in 2011
Acne vulgaris is a common disorder of the pilosebaceous follicle with multiple pathogenic factors. Topics like antibiotic treatment, antibiotic resistant, topical agents, are covered.
Topical Approaches in Combination Therapy for Acne (Pharmacist Edition)
This article delves into appropriate use of topical therapies for acne treatment. Appropriate agent selection, tolerance, adherence, follow-up, and considerations like complexity of treatment are discussed.
Adapalene 0.1% and Benzoyl Peroxide 2.5%: A Novel Combination for Treatment of Acne Vulgaris
Topical products commonly used to treat acne include retinoids and antimicrobials, due to their effects on different components of pathogenesis. Accordingly, a fixed combination of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% was developed (Epiduo™, Galderma) and was approved by the US FDA for the treatment of acne.
Topical Acne Therapy: Current and Advanced Options for Optimizing Adherence
Topical treatment is the mainstay for mild acne, and adjunctive to oral or hormonal therapy for moderate acne. This article explores recent formulary advances and offers clinical strategies that can encourage adherence and improve treatment outcomes.
Therapeutic Advances in Topical Acne Agents
The multifactorial nature of acne vulgaris often requires a combination of topical and/or oral agents for successful management. Common challenges of this multipronged approach include the potential development of skin irritation, which results in nonadherence, as well as concern over bacterial resistance.
Adapalene as Acne Treatment
Adapalene is a designer retinoid, with a similar molecular make-up with vitamin A. A guide to patient use, at what point in time should patients expect improvement, mechanism of action, side-effects, and other drug interactions are discussed in this article.
Topical Agents Used in the Management of Hyperpigmentation
Disorders of hyperpigmentation are difficult to treat, particularly in dark-skinned individuals. The goal is to reduce the hyperpigmentation without causing undesirable hypopigmentation or irritation in the surrounding normally pigmented skin. The psychosocial impact caused by these disorders must be considered.
Topical Tazarotene Therapy for Psoriasis, Acne Vulgaris, and Photoaging
Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.
Update on Topical Acne Treatments
Topical acne treatment can positively benefit patients with acne. This review summarizes clinical and prescribing information on currently available topical agents. The efficacy of the medications included in this report is supported by properly designed randomized clinical trials.